S. Junk

Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines

M. Schrappe, M. Stanulla, B. Schlegelberger, 2015, Klinische Pädiatrie.

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

D. Steinemann, M. Muckenthaler, R. Houlston, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group

M. Muckenthaler, J. Vijayakrishnan, R. Houlston, 2023, Journal of Experimental & Clinical Cancer Research.

Prognostic impact of IKZF1 deletions in association with vincristine–dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95

M. Schrappe, A. Möricke, C. Kratz, 2017, Leukemia.

Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia

H. Schünemann, M. Schrappe, S. Igel, 2021, Leukemia.

TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia

M. Schrappe, A. Möricke, C. Kratz, 2019, Haematologica.

Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia

R. Houlston, A. Franke, M. Schrappe, 2021, Journal of clinical medicine.

Proteasome inhibitor bortezomib induces apoptosis in prednisone-resistant childhood acute lymphoblastic leukemia cells

M. Schrappe, M. Stanulla, B. Schlegelberger, 2010 .

Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia

A. Borkhardt, M. Schrappe, M. Valsecchi, 2023, HemaSphere.